Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 1, 2005, Pages 31-40

  Corrao, Giovanni ^a   Botteri, Edoardo ^a   Bagnardi, Vincenzo ^a   Zambon, Antonella ^a   Carobbio, Alessandra ^a   Falcone, Chiara ^a   Leoni, Olivia ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Local Health Dept Prov of Varese   (Italy)

Author keywords

Antibacterials; Arrhythmia; Automated databases; Case control design; Cohort design; Fluoroquinolones; Macrolides; Prescription sequence symmetry design

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; ENOXACIN; ERYTHROMYCIN; FLURITHROMYCIN; JOSAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MIOKAMYCIN; MONOBACTAM DERIVATIVE; NORFLOXACIN; OFLOXACIN; PENICILLIN G; ROKITAMYCIN; ROXITHROMYCIN; RUFLOXACIN; SPIRAMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HUMAN; ITALY; MAJOR CLINICAL STUDY; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; ARRHYTHMIA; CASE-CONTROL STUDIES; CIPROFLOXACIN; CLARITHROMYCIN; COHORT STUDIES; COMMUNITY HEALTH PLANNING; DATABASES, FACTUAL; DRUG MONITORING; ERYTHROMYCIN; HUMANS; ITALY; MIOCAMYCIN; NORFLOXACIN; OFLOXACIN; PHARMACOEPIDEMIOLOGY; RISK FACTORS;

EID: 11844250613     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1019     Document Type: Article

References (26)

1. Strom BL. What is pharmacoepidemiology? In Pharmacoepidemiology (3rd edn), Strom BL (ed.). John Wiley & Sons: New York, 2000: 3-15.
2. Petri H, Leufkens H, Naus J, Silkens R, van Hessen P, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43 433-439.
3. Suissa S. Pharmacoepidemiology, overview. In Encyclopedia of Epidemiologic Methods, Gail MH, Benichou J (eds). John Wiley & Sons: New York, 2000: 702-712.
4. Petri H, De Vet HC, Naus J, Urquhart J. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescriptions drugs in large populations. Stat Med 1988; 7 1171-1175.
5. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-581.
6. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-484.
7. Lindberg G, Hallas J. Cholesterol-lowering drugs and antidepressants: a study of prescription symmetry. Pharmacoepidemiol Drug Safe 1998; 7: 399-402.
8. Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea: a symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000; 14: 1479-1484.
9. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2002; 45: 415-427.
10. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro, N. Safety of non-arrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Saf 2002; 25: 263-286.
11. Breslow NE, Day NE. Statistical Methods in Cancer Research: The Design and Analysis of Cohort Studies, Vol. 2. International Agency for Research on Cancer: Lyon, France, 1987 (IARC scientific publications no. 82.): 1-46.
12. Rothman KJ, Greenland S. Modern Epidemiology. Lippincott-Raven Publishers: Philadelphia, 1998; 94.
13. Breslow NE, Day NE. Statistical Methods in Cancer Research: The Analysis of Case-Control Studies, Vol. 1. International Agency for Research on Cancer: Lyon, France, 1980 (IARC scientific publications no. 32.): 247-279.
14. Ohtani H, Taninaka C, Hanada E, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 2000; 44: 2630-2637.
15. Milberg P, Eckardt L, Bruns H-J, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. Pharmacol Exp Ther 2002; 303: 218-225.
16. Clark DW, Layton D, Wilton LV, Pearce GL, Shakir SAW. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials. Drug Saf 2001; 24: 1143-1154.
17. + channel HERG. Mol Pharmacol 2001; 59: 122-126.
18. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21: 1468-1472.
19. Owens RC, Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663-668.
20. Sterne JAC, Davey Smith G, Cox DR. Sifting the evidence: what's wrong with significance tests? Another comment on the role of statistical methods. Br Med J 2001; 322: 226-231.
21. Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiologic research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-1770.
22. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Safe 1998; 7: 275-280.
23. Eland IA, Huerta-Alvarez C, Stricker BHC, Garcia-Rodriguez LA. The risk of acute pancreatitis associated with acid suppressing drugs. Br J Clin Pharmacol 2000; 49: 473-478.
24. Evans JMM, MacDonalds M. Misclassification and selection bias in case-control studies using an automated database. Pharmacoepidemiol Drug Safe 1997; 6: 313-318.
25. Walker AM. Confounding by indication. Epidemiology 1996; 7: 335-336.
26. Schulzer M, Mancini GBJ. "Unqualified success" and "unmitigated failure": number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996; 25: 704-712.